Observe Medical - DOC (Declaration of Conformity) signed for UnoMeter[TM ]Safeti[TM] Plus and subscription form for equity investment received from industrial partner

12 Nov 2024 14:41 CET

Oslo, November 12[th], 2024 - Observe Medical ("the Company" or "Observe
Medical") has today signed the DOC (Declaration of Conformity). This marks the
final step for the establishment of a high-volume manufacturing platform for the
UnoMeterT product portfolio, consisting of UnoMeterT 500 and UnoMeterT SafetiT
Plus. The DOC is the final regulatory documentation that needs to be approved
for the Observe Medical group to be able to accept and receive orders for
UnoMeterT SafetiT Plus from customers and also accept other relevant commercial
and financial commitments related thereto.

The Company further announces that Jiangsu Hongxin Medical Technology Co., Ltd
("JHMT"), which is the Company's largest industrial partner within manufacturing
and supply, has signed a binding subscription form to subscribe for shares in
the Company for an amount of NOK 3,300,000 at a subscription price of NOK 0.40
per share. The subscription is conditional upon the board of directors of the
Company resolving to issue the new shares based on the board authorisation
granted by the Company's extraordinary general meeting on 17 July 2024, which
resolution is intended to be passed as soon as JHMT has been able to establish a
securities account in which the new shares can be held. JHMT is currently
working with the Company's registrar to open such securities account. The
proceeds from the potential share issue will be used to contribute to the
Company's working capital requirements. In addition, the Company is in dialogue
with strategic and financial partners to evaluate options to further strengthen
its working capital situation.

Jørgen Mann, CEO of Observe Medical, commented, "With the re-introduction of
UnoMeter[TM] Safeti[TM] Plus we now have all the products that are part of the
agreement with Convatec/Unomedical back on the market and thereby we have the
means to accelerate our commercial journey further. Our organization has been
fighting hard to get to this point as fast as possible without leaving any space
to compromise on the superior product quality of the UnoMeters which have been
the foundation of their market leading position for the last several decades".

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

More information:
Access the news on Oslo Bors NewsWeb site